2019-11-14T17:48:06-06:00 2018-12-31 911194016 CLARK NUBER PS 10900 NE 4TH STREET SUITE 1400 BELLEVUE WA 98004 990 2018-01-01 911893957 THE MAX FOUNDATION MAXF 4257788660 1107 NE 45TH NO 230 SEATTLE WA 98105 PATRICIA M PEARCE CFO & VP, ADMINISTRATION 4257788660 2019-11-14 1 JANE M SEARING P00000565 4254544919 2019-11-14 65.158.230.194 2019-11-14 10:39:00 PS P DE1D2BBAE0F1147E7A7EA18DABEA7E867F199504 2DE068ACBFA10A31F139242116409E8904B6E6F4 2018 2020-03-31 21:24:44Z PATRICIA M PEARCE 1107 NE 45TH NO 230 SEATTLE WA 98105 31017810 0 X WWW.THEMAXFOUNDATION.ORG X 1997 WA AT THE MAX FOUNDATION WE BELIEVE ALL PEOPLE LIVING WITH CANCER DESERVE ACCESS TO THE BEST TREATMENT, CARE, AND SUPPORT. AS SUCH, WE DECREASE PREMATURE MORTALITY OF CANCER BY CHANNELING HUMANITARIAN DONATIONS OF INNOVATIVE ONCOLOGY PRODUCTS TO UNDERSERVED POPULATIONS IN COUNTRIES WHERE THOSE PRODUCTS ARE NOT LOCALLY AVAILABLE. 7 6 17 336 0 4385 18308593 27791248 2583674 3221057 4592 4472 -133096 -74110 20763763 30942667 13544588 24004506 0 0 1515651 1822840 0 66324 625231 2643141 2779985 17703380 28673655 3060383 2269012 7650487 9957805 197802 236108 7452685 9721697 X AT THE MAX FOUNDATION WE BELIEVE ALL PEOPLE LIVING WITH CANCER DESERVE ACCESS TO THE BEST TREATMENT, CARE, AND SUPPORT. WE DECREASE PREMATURE MORTALITY OF CANCER BY CHANNELING HUMANITARIAN DONATIONS OF LIFE-SAVING ONCOLOGY PRODUCTS TO UNDERSERVED POPULATIONS IN COUNTRIES WHERE THOSE PRODUCTS ARE NOT LOCALLY AVAILABLE. 0 0 27029436 24004506 3221057 A KEY FOCUS OF THE ORGANIZATION IS EXPANDING HUMANITARIAN ACCESS TO INNOVATIVE TREATMENTS FOR CANCER IN LOW- AND MIDDLE-INCOME COUNTRIES. WE RECEIVE DONATIONS OF ONCOLOGY PRODUCTS FROM DRUG MANUFACTURERS AND CHANNEL THEM TO INDIVIDUAL PATIENTS VIA OUR NETWORK HEALTHCARE PROVIDERS AND CANCER TREATMENT CENTERS. THIS ACCESS TO MEDICINES IS ENABLED THROUGH OUR PATIENT-CENTERED TREATMENT ACCESS MODEL KNOWN AS MAX ACCESS SOLUTIONS. OUR PRIMARY CLIENT IS A PATIENT WHO IS TREATED BY ONE OF OUR PARTNER PHYSICIANS, DIAGNOSED WITH A SPECIFIC CANCER, AND PRESCRIBED A MEDICATION FOR WHICH THE ONLY AVAILABLE FORM OF ACCESS IS A HUMANITARIAN CHANNEL THROUGH MAX ACCESS SOLUTIONS. WE USE A SOPHISTICATED WEB-ENGINE PLATFORM DEVELOPED IN-HOUSE TO ALLOW US TO WORK IN REAL TIME WITH HEALTHCARE PROVIDERS AND CREATE INDIVIDUALIZED PROGRAM LIFE CYCLES TO MEET EACH PATIENT'S NEEDS. WE FURTHER ACT AS HEALTHCARE NAVIGATORS FOR THESE PATIENTS, HELPING THEM WALK THROUGH THE ACCESS PROGRAM ENVIRONMENT. IN ORDER TO OPTIMIZE TREATMENT, WITHIN OUR CAPABILITIES WE PROVIDE WRAPAROUND SUPPORT THAT INCLUDES ACCESS TO DIAGNOSTIC TESTING, EMOTIONAL AND LOGISTICAL SUPPORT, INFORMATION RESOURCES AND EDUCATION, AS WELL AS ADVOCATING ON THEIR BEHALF WHEN NEEDED. WE ALSO STRENGTHEN THE COMMUNITIES AROUND PATIENTS BY SUPPORTING PATIENT ORGANIZATIONS AND CREATING AWARENESS INITIATIVES IN LOCAL AND GLOBAL COMMUNITIES. 27029436 1 1 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 1 0 1 1 1 1 1 0 0 0 0 0 1 0 0 0 0 0 0 1 0 1 0 0 0 1 1 1 1 0 0 1 X 15 0 1 17 1 1 1 1 IN MY TH AR SF 0 0 0 0 0 0 0 0 0 0 X 7 6 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 X X PATRICIA GARCIA-GONZALEZ 4257788660 1107 NE 45TH NO 230 SEATTLE WA 98105 PAULA BOULTBEE PRESIDENT 5.00 2.00 X X 0 0 0 DAVID TINGSTAD SECRETARY 2.00 2.00 X X 0 0 0 JERRY SCOTT CPA TREASURER 5.00 2.00 X X 0 0 0 ROBERT FARMER BOARD MEMBER 2.00 2.00 X 0 0 0 TRACEY HIGGINS BOARD MEMBER 2.00 2.00 X 0 0 0 GRANT RUBENSTEIN BOARD MEMBER 5.00 2.00 X 0 0 0 JERALD JERRY RADICH MD BOARD MEMBER 5.00 2.00 X 0 0 0 PATRICIA GARCIA-GONZALEZ CEO 50.00 5.00 X X 207685 0 14993 PATRICIA M PEARCE CHIEF FINANCIAL OFFICER 40.00 2.00 X 66887 0 4654 ERIN L SCHWARTZ VP, GLOBAL ENGAGEMENT 40.00 0.00 X 125009 0 10035 CRAIG ANDERSON DIRECTOR OF IT 40.00 0.00 X 106515 0 11229 MICHAEL WRIGGLESWORTH DIRECTOR OF GLOBAL IT SOLUTIONS 40.00 0.00 X 107530 0 0 613626 0 40911 4 0 1 0 ANDREW W LYON LLC PO BOX 651 PLAINFIELD IN 46168 TRAVEL & LOGISTICS SERVICES 136553 1 27791248 25866341 27791248 PATIENT CARE 624100 2710083 2710083 MEDICAL TEST KITS 624100 510974 510974 3221057 4472 4472 11 11 75143 -75143 -75143 REIMBURSEMENTS 900099 984 984 38 38 1022 30942667 3221057 0 -69638 24004506 24004506 654537 257844 269119 127574 51841 51841 913834 640305 163579 109950 89033 62340 17632 9061 113595 67279 29929 16387 13781 4676 9105 177217 177217 66324 66324 225807 119281 97064 9462 141523 11349 130174 115423 31799 50861 32763 40472 23970 10663 5839 140587 83265 37040 20282 313799 156900 62760 94139 36893 36893 13537 13537 SPONSORED EDU. PROJECTS 681328 681328 PROGRAM COORDINATION 498588 498588 DISTRIBUTION & SHIPPING 337623 337623 43407 7891 32240 3276 28673655 27029436 1018988 625231 2607834 1738682 30254 63673 242770 73199 622 4140297 6286524 25500 19839 287733 206813 113677 80920 659726 1524775 7650487 9957805 197802 228930 0 7178 197802 236108 X 5485960 2763214 1966725 6958483 7452685 9721697 7650487 9957805 2269012 0 X 0 1 X 1 0 X 1068789 2765925 13925957 18308593 27791248 63860512 1068789 2765925 13925957 18308593 27791248 63860512 52823645 11036867 4071 4605 5680 5434 4483 24273 590 1120 4968 3693 1022 11393 63896178 12221771 0.17270 0.17900 X THE MAX FOUNDATION QUALIFIES AS A PUBLICLY SUPPORTED CHARITY UNDER THE FACTS AND CIRCUMSTANCES EXCEPTION PROVIDED TO IRC SECTION 509(A)(1) CHARITIES UNDER TREAS. REG. SEC. 1.170A-9(E)(3). THE FOUNDATION DOES NOT RECEIVE AT LEAST ONE THIRD OF ITS SUPPORT FROM THE PUBLIC. IT DOES HOWEVER MEET THE TESTS REQUIRED UNDER THE FACTS AND CIRCUMSTANCE TEST: I. THE FOUNDATION NORMALLY MEETS THE PUBLIC SUPPORT TEST AS PROVIDED IN THE REGULATIONS. THE AGGREGATE PUBLIC SUPPORT PERCENTAGE FOR THE YEARS ENDED DECEMBER 31, 2017, 2016, 2015, 2014, AND 2013 IS 27.73% 41.45%, 30.50%, 37.79%, AND 40.92%, RESPECTIVELY. II. THE FOUNDATION CARRIES ON A BONA FIDE CONTINUOUS PUBLIC SOLICITATIONS PROGRAM. ITS FUNDRAISING EFFORTS INCLUDE ANNUAL MAILINGS TO SOLICIT FUNDS, PUBLISHING OF AN ANNUAL REPORT TO EDUCATE ITS DONOR BASE AND FURTHER SOLICIT DONATIONS, AND OTHER FUNDRAISING ACTIVITES. IN 2017, THE FOUNDATION HELD ITS FIRST FUNDRAISING GALA, RAISING OVER $98,000. IN 2017 AND 2018 WE ALSO HAD INTERNATIONAL FUNDRAISING EVENTS CALLED MAX GLOBAL EXPERIENCE WHICH RAISED OVER $109,000 AND OVER $80,000, RESPECTIVELY, FROM THE GENERAL PUBLIC. SINCE 2017 FIVE MULTINATIONAL PHARMACEUTICAL COMPANIES JOINED THE FOUNDATION IN WHAT WE CALL A HUMANITARIAN PARTNERSHIP FOR ACCESS TO CANCER TREATMENT (PACT). THROUGH THESE HUMANITARIAN COLLABORATIONS, EACH COMPANY HAS COMMITTED TO DONATE PRESCRIBED MEDICATIONS FOR A DIFFERENT NUMBER OF PATIENTS WITHIN THEIR CAPABILITIES, AND ALL HAVE COMMITTED THEIR SUPPORT FOR AS LONG AS EACH PATIENT NEEDS IT. III. DURING THE YEARS ENDED DECEMBER 31, THE FOUNDATION HAD THE FOLLOWING SUPPORTERS, RESPECTIVELY: 2014:INDIVIDUALS - 78 CORPORATIONS - 3 FOUNDATIONS - 0TOTAL - 812015:INDIVIDUALS - 307 CORPORATIONS - 8 FOUNDATIONS - 1TOTAL - 3162016:INDIVIDUALS - 371 CORPORATIONS - 24 FOUNDATIONS - 2TOTAL - 3972017:INDIVIDUALS - 676 CORPORATIONS - 35 FOUNDATIONS - 2TOTAL - 7132018:INDIVIDUALS - 377 CORPORATIONS - 42 FOUNDATIONS - 2TOTAL - 421 IV. THE PUBLIC NATURE OF THE FOUNDATION'S GOVERNING BOARD - THE FOUNDATION HAS A BOARD OF DIRECTORS THAT INCLUDES PROFESSIONALS, COMMUNITY LEADERS, AND OTHER PERSONS WITH EXPERTISE IN DIFFERENT DISCIPLINES. IN ADDITION, THE FOUNDATION HAS A MEDICAL ADVISORY BOARD AND A STRATEGIC INNOVATION ADVISORY BOARD. OUR MEDICAL ADVISORY BOARD INCLUDES SPECIALISTS WHO ARE KEY OPINION LEADERS IN THE FIELD OF ONCOLOGY AND HEMATOLOGY. BASED ALL AROUND THE WORLD THESE EXPERT PHYSICIANS ARE FORMATIVE IN LEADING RESEARCH AND MANAGING PATIENT CARE AT THEIR CENTERS OF EXCELLENCE. OUR STRATEGIC INNOVATION ADVISORY BOARD HAIL FROM BOTH THE PUBLIC AND PRIVATE SECTORS AND INCLUDE GLOBAL LEADERS FROM THE FIELD OF GLOBAL HEALTH, FUNDRAISING, BUSINESS, AND COMMUNICATIONS. V. THE FOUNDATION SUPPORTS GLOBAL HEALTH EFFORTS BY: - MAKING TREATMENT, CARE, AND SUPPORT AVAILABLE IN LOWER INCOME COUNTRIES AND THEREBY PREVENTING AVOIDABLE CANCER DEATHS AROUND THE WORLD- HELPING TO CLOSE THE CANCER DIVIDE BETWEEN HIGH INCOME AND LOWER INCOME COUNTRIES THROUGH HUMANITARIAN ACCESS TO TREATMENT, CARE AND SUPPORT. - CREATING A MODEL THAT ENABLES THE PRIVATE SECTOR TO HELP CANCER PATIENTS IN NEED.- STRENGTHENING HEALTH SYSTEMS AND LOCAL SUPPORTS THROUGH WRAPAROUND SERVICES FOR PATIENTS AND THEIR COMMUNITIES.VI. MAX ACCESS SOLUTIONS IS THE FOUNDATION'S OPERATIONAL PROGRAM THROUGH WHICH HUMANITARIAN DONATIONS OF APPROVED ONCOLOGY PRODUCTS ARE CHANNELED TO PATIENTS IN NEED. MAX ACCESS SOLUTIONS IS MEANT TO BE A BRIDGE FOR ACCESS TO TREATMENT SPECIFICALLY WITHIN LOW- AND MIDDLE-INCOME COUNTRIES WHERE THE BURDEN OF DISEASE IS HIGH AND LOCAL GOVERNMENT ACCESS PROGRAMS MAY NOT BE CURRENTLY FEASIBLE.WITHIN MAX ACCESS SOLUTIONS, COMPANIES DONATE PRODUCT TO THE FOUNDATION AND THE ORGANIZATION CHANNELS PRODUCT AT ITS DISCRETION TO PATIENTS IN NEED THROUGH THEIR TREATING PHYSICIAN AND WITHIN THE SCOPE OF ITS COLLABORATION AGREEMENTS. VETTED HEALTH CARE PROVIDERS IN LOW- AND MIDDLE-INCOME COUNTRIES INITIATE THE PRODUCT REQUEST AND MANAGE TREATMENT OF PATIENTS RECEIVING PRODUCT FROM THE FOUNDATION. THE FOUNDATION WORKS THROUGH A THIRD-PARTY LOGISTICS PROVIDER WHO, AS ITS AGENT, RECEIVES PRODUCT FROM MANUFACTURERS AND SHIPS IT TO END USERS ON THE ORGANIZATION'S BEHALF.AT THE CENTER OF OUR MODEL IS A PATIENT WHO HAS BEEN DIAGNOSED BY ONE OF OUR PARTNER PHYSICIANS WITH CANCER AND PRESCRIBED A TREATMENT IN OUR PORTFOLIO FOR WHICH NO LOCAL ACCESS EXISTS. WORKING IN COLLABORATION WITH A ROBUST NETWORK OF LEADING CANCER TREATING INSTITUTIONS AND PHYSICIANS, DRUG MANUFACTURERS, AN INTERNATIONAL DISTRIBUTOR, AND LOCAL PATIENT SUPPORT ORGANIZATIONS, WE PROVIDE HUMANITARIAN ACCESS TO THE TREATMENT WITH THE AIM THAT EACH REQUIRED DAILY DOSE REACHES THE INTENDED PATIENT AT THE RIGHT TIME, WHILE STRENGTHENING THE LOCAL HEALTHCARE SYSTEM.IN 2018, THE FOUNDATION DELIVERED 4,585,795 DAILY DOSES INTO THE HANDS OF PATIENTS. WE WORKED WITH A GLOBAL NETWORK OF 290 DOCTORS WHO REFERRED CANCER PATIENTS TO US FROM AROUND THE WORLD. WE OVERSAW DRUG SHIPMENTS TO 72 COUNTRIES. WE TRACKED OVER 15,300 INDIVIDUAL PATIENTS IN OUR REAL-TIME TRACKING SYSTEM SPECIFICALLY DEVELOPED TO MONITOR EACH PATIENT'S TREATMENT LIFECYCLE. SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: MISCELLANEOUS INCOME - 2014 AMOUNT: $ 590. 2015 AMOUNT: $ 1,120. 2016 AMOUNT: $ 4,968. 2017 AMOUNT: $ 3,693. 2018 AMOUNT: $ 1,022. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 74559 33552 41007 213174 173261 39913 80920 LEASE DEPOSIT 9047 DUE TO/FROM MAXAID 1515728 1524775 1 CENTRAL AMERICA AND THE CARIBBEAN 0 3 PROGRAM SERVICES, GRANTS EDUCATIONAL WORKSHOPS, PATIENT COUNSELING, DIRECT DRUG DONATION 64000 EAST ASIA AND THE PACIFIC 2 11 PROGRAM SERVICES, GRANTS EDUCATIONAL WORKSHOPS, PATIENT COUNSELING, DIRECT DRUG DONATION 431000 EUROPE (INCLUDING ICELAND AND GREENLAND) 0 0 PROGRAM SERVICES EDUCATIONAL WORKSHOPS, PATIENT COUNSELING 25000 NORTH AMERICA 0 2 PROGRAM SERVICES, GRANTS EDUCATIONAL WORKSHOPS, PATIENT COUNSELING, DIRECT DRUG DONATION 56000 RUSSIA AND NEIGHBORING STATES 0 2 PROGRAM SERVICES, GRANTS EDUCATIONAL WORKSHOPS, PATIENT COUNSELING, DIRECT DRUG DONATION 72000 SOUTH AMERICA 1 6 PROGRAM SERVICES, GRANTS EDUCATIONAL WORKSHOPS, PATIENT COUNSELING, DIRECT DRUG DONATION 292000 SOUTH ASIA 1 21 PROGRAM SERVICES, GRANTS EDUCATIONAL WORKSHOPS, PATIENT COUNSELING, DIRECT DRUG DONATION 342000 SUB-SAHARAN AFRICA 1 6 PROGRAM SERVICES, GRANTS EDUCATIONAL WORKSHOPS, PATIENT COUNSELING, DIRECT DRUG DONATION 495000 CENTRAL AMERICA AND THE CARIBBEAN 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 140000 EAST ASIA AND THE PACIFIC 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 10229000 EUROPE (INCLUDING ICELAND AND GREENLAND) 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 200000 MIDDLE EAST AND NORTH AFRICA 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 388000 NORTH AMERICA 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 9000 RUSSIA AND NEIGHBORING STATES 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 2437000 SOUTH AMERICA 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 1086000 SOUTH ASIA 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 4079000 SUB-SAHARAN AFRICA 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 5145000 EUROPE (INCLUDING ICELAND AND GREENLAND) 0 0 FUNDRAISING 5 51 0 0 5 51 1777000 23713000 25490000 EAST ASIA & THE PACIFIC DIAGNOSTIC TESTING 19460 DIAGNOSTIC EQUIPMENT BOOK RUSSIA AND NEIGHBORING STATES DIAGNOSTIC TESTING 40530 DIAGNOSTICS EQUIPMENT BOOK SOUTH AMERICA DIAGNOSTIC TESTING 40550 DIAGNOSTICS EQUIPMENT BOOK SOUTH AMERICA DIAGNOSTIC TESTING 10310 DIAGNOSTICS EQUIPMENT BOOK SOUTH AMERICA DIAGNOSTIC TESTING 16870 DIAGNOSTICS EQUIPMENT BOOK SUB-SAHARAN AFRICA DIAGNOSTIC TESTING 21257 DIAGNOSTICS EQUIPMENT BOOK SUB-SAHARAN AFRICA DIAGNOSTIC TESTING 5820 DIAGNOSTICS EQUIPMENT BOOK SUB-SAHARAN AFRICA DIAGNOSTIC TESTING 37017 DIAGNOSTICS EQUIPMENT BOOK SUB-SAHARAN AFRICA DIAGNOSTIC TESTING 26910 DIAGNOSTICS EQUIPMENT BOOK SUB-SAHARAN AFRICA DIAGNOSTIC TESTING 16080 DIAGNOSTICS EQUIPMENT BOOK 10 0 DRUG CENTRAL AMERICA AND THE CARIBBEAN 15 140105 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG EAST ASIA AND THE PACIFIC 211 10229410 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG EUROPE (INCLUDING ICELAND AND GREENLAND) 3 199832 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG MIDDLE EAST AND NORTH AFRICA 18 387888 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG NORTH AMERICANORTH AMERICA 1 8775 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG SOUTH AMERICA 68 2436952 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG SOUTH ASIA 22 1086257 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG SUB-SAHARAN AFRICA 120 4078514 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG SUB-SAHARAN AFRICA 265 5144881 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE 1 1 0 0 0 0 PART I, LINE 2: ALL GRANTS TO FOREIGN ENTITIES OR INDIVIDUALS ARE MADE SUBJECT TO A WRITTEN AGREEMENT OR AWARD LETTER THAT CLEARLY DEFINES DELIVERABLES. THE MAX FOUNDATION MAINTAINS A PROGRAM DATABASE IN ORDER TO TRACK DOCUMENTATION OF GRANT REQUESTS, QUALIFIED GRANTEES, AND FULFILMENT OF GRANT REQUESTS. PROGRAM STAFF MEMBERS MONITOR THE EXECUTION OF GRANT DELIVERABLES TO ENSURE THAT THE TERMS OF THE AGREEMENT ARE FULFILLED ON A TIMELY BASIS. PART I, LINE 3: THE EXPENDITURES REPORTED ON SCHEDULE F, PART I, LINE 3 ARE ON THE ACCRUAL BASIS OF ACCOUNTING. PART IV, LINE 1: FORM 926 IS NOT REQUIRED TO BE FILED BECAUSE THE TRANSFER TO A FOREIGN CORPORATION DOES NOT MEET THE REPORTING REQUIREMENTS IN IRC SEC. 6038(A)(1)(A). X X X 0 COMMUNITY COUNSELING SERVICE CO LLC 100 MONTGOMERY STREET SAN FRANCISCO CA 94104 ASSESSMENT OF DEVELOPMENT OPERATIONS AND CREATION OF FUNDRAI 0 0 40000 -40000 GMUR CIVIL SOCIETY CONSULTING ROUTE DE FLORISSANT 130 CONCHES SZ DEVELOP CONCRETE PLANS FOR IMPLEMENTATION OF RECOMMENDATIONS 0 0 21809 -21809 61809 -61809 WA X X X 0 0 0 0 0 0 0 0 0 PATRICIA GARCIA-GONZALEZ CEO 197685 0 10000 0 0 0 0 0 14993 0 222678 0 0 0 INES GARCIA-GONZALEZ SEE PART V 51841 SEE PART V 0 SCH L, PART IV, BUSINESS TRANSACTIONS INVOLVING INTERESTED PERSONS: (A) NAME OF PERSON: INES GARCIA GONZALEZ(B) RELATIONSHIP BETWEEN INTERESTED PERSON AND ORGANIZATION: FAMILY MEMBER OF PATRICIA GARCIA-GONZALEZ, CEO.(D) DESCRIPTION OF TRANSACTION: CONTRACTOR X 280488 25858481 COMM VOL AVG WHOLESALE X PHONE SLEEVES 500 7500 FMV 0 0 1 0 PART I, COLUMN (B): THE NUMBER IN COLUMN B REPRESENTS THE NUMBER OF TABS CONTRIBUTED. FORM 990, PART I, LINE 6, VOLUNTEERS: IN 2018, THE MAX FOUNDATION LED A GLOBAL CANCER AWARENESS CAMPAIGN AND PROVIDED GRANTS TO LOCAL PATIENT ASSOCIATIONS. THESE PARTNER PATIENT ASSOCIATIONS HELD 30 EVENTS AIMED AT INCREASING AWARENESS OF CANCER. VOLUNTEERS HELPED TO ORGANIZE AND PROVIDE SUPPORT DURING THE EVENTS. VOLUNTEERS ALSO STAFFED CANCER AWARENESS BOOTHS AT TWO ADDITIONAL CONFERENCES. SEVEN MEMBERS OF THE BOARD OF DIRECTORS ARE ALSO VOLUNTEERS. FORM 990, PART VI, SECTION B, LINE 11B THE TAX RETURN IS PREPARED BY AN OUTSIDE ACCOUNTANT. AFTER PREPARATION, THE FINANCE COMMITTEE PERFORMS A REVIEW OF THE RETURN. THE RETURN IS THEN FILED WITH THE IRS. A COPY IS PROVIDED TO THE BOARD OF DIRECTORS PRIOR TO FILING WITH THE INTERNAL REVENUE SERVICE. FORM 990, PART VI, SECTION B, LINE 12C THE BOARD HAS ADOPTED A CONFLICT OF INTEREST POLICY AND THE POLICY IS REVIEWED ON AN ANNUAL BASIS. EACH YEAR, BOARD MEMBERS AND OFFICERS MUST REVIEW THE POLICY AND DETERMINE IF ANY CONFLICT OF INTERESTS EXIST. ANNUALLY, THE DISCLOSURES WERE REVIEWED BY THE EXECUTIVE ASSISTANT. SHOULD A CONFLICT ARISE, IT WOULD BE REVIEWED BY THE CFO, CEO AND BOARD TREASURER. NO BOARD MEMBER OR OFFICER MAY VOTE ON ANY MATTER UNDER CONSIDERATION IN WHICH SUCH PERSON HAS A CONFLICT OF INTEREST. FURTHER, ANY PERSON WITH A MATERIAL CONFLICT OF INTEREST IN ANY DECISION SHOULD BE ABSENT FROM THE ROOM DURING THE BOARD'S REVIEW, INCLUDING ITS VOTE, ON THE DECISION IN QUESTION. FORM 990, PART VI, SECTION B, LINE 15 THE CEO HAS A CONTRACT WITH THE BOARD, UPDATED AND APPROVED ON JUNE 21, 2018 BY THE COMPENSATION COMMITTEE. IN THIS CONTRACT, A BASE SALARY AND A YEARLY PERCENTAGE INCREASE HAS BEEN ESTABLISHED BY THE COMPENSATION COMMITTEE, AS WELL AS A YEARLY BONUS. AN HR CONSULTANT, COMPENSATION ANALYSIS AND A WRITTEN PERFORMANCE EVALUATION ALL WENT INTO THE RENEWAL OF THE CEO CONTRACT DURING 2018. THE CFO WAS OFFICIALLY HIRED AS AN EMPLOYEE IN JULY 2018. BOTH THE CEO AND THE BOARD COMPENSAITON COMMITTEE REVIEWED AND DETERMINED COMPENSATION. FORM 990, PART VI, SECTION C, LINE 19 THE GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE PROVIDED UPON REQUEST. MAXSTATION MALAYSIA SDN BHD UNIT 1302 LOBBY 1 BLOCK A DAMAN SELANGOR MY 320492996 PATIENT ORIENTED PROGRAMS MY 135190 63172 THE MAX FOUNDATION MAXAID 1107 NE 45TH NO 230 SEATTLE WA 98105 352577906 SUPPORT MAX FOUNDATION WA 501(C)(3) LINE 12A, I THE MAX FOUNDATION 1 THE MAX FOUNDATION SOUTH AFRICA TRUST 10 COSMOSPLACE DOORNPOORT PRETORIA SF 0186 TO SUPPORT MAX FOUNDATION SF MAX FOUNDATION T -37290 5874 1.00000 1 0 1 0 1 0 0 0 0 0 0 0 1 0 1 1 0 1 0 0 MAXAID L 2551500 BOOK